Anthony Johnson, Goldfinch Bio CEO (Goldfinch via YouTube)
Gilead-partnered Goldfinch Bio lands $100M as it pivots to clinical stage biotech
A year after landing $109 million in cash for an early-stage discovery deal with Gilead, Goldfinch Bio has scored a similar bounty from investors …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
